毕井泉被查；默沙东中国换帅丨医药早参

Group 1 - Bi Jingquan, a member of the National Committee of the Chinese People's Political Consultative Conference, is under investigation for serious violations of discipline and law [1] - He previously served as the head of the National Medical Products Administration and resigned due to the Changchun Changsheng vaccine scandal [1] Group 2 - Merck has appointed Kyle Tattle as the new President of Merck China, succeeding Anna Van Acker, who will take on a strategic role in the Human Health Division [2] - During Anna Van Acker's tenure, Merck China made significant progress in introducing innovative drugs and promoting HPV vaccines [2] - Kyle Tattle's extensive experience is expected to enhance Merck's market expansion and research collaboration in China [2] Group 3 - Shuyou Pharmaceutical announced that its drug STSP-0601 is currently in the public announcement period, which ends on June 3, 2025 [3] - The stock price of Shuyou Pharmaceutical has fluctuated significantly due to market interest in STSP-0601, which could potentially accelerate its market entry if it enters the priority review process [3] Group 4 - Fosun Pharma's self-developed MEK inhibitor, Luwo Mei Tini, has been approved for domestic marketing, targeting rare blood tumors [4] - The drug is indicated for treating Langerhans cell histiocytosis in adults and symptomatic plexiform neurofibromas in children aged 2 and above [4] - This approval fills a treatment gap for rare tumors and has promising clinical efficacy and safety [4] Group 5 - Haichuang Pharmaceutical's AR inhibitor, Dihenzalutamide soft capsules, have been approved, marking the first domestic innovative drug for treating metastatic castration-resistant prostate cancer [5] - The drug is intended for patients who have progressed after receiving abiraterone acetate and chemotherapy [5] - This approval ends Haichuang Pharmaceutical's "zero drug revenue" status, but challenges remain regarding commercialization and competition from generics [5]